FDA Approves Indication for GE Healthcare's Visipaque for Use With Coronary CT Angiography


May 2, 2017—GE Healthcare announced that it has received an indication approval from the US Food and Drug Administration (FDA) for its imaging agent Visipaque (iodixanol) injection.

The Visipaque 320-mg iodine/mL iso-osmolar agent is now approved for use in coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of adult and pediatric patients who are 12 years of age or older with suspected coronary artery disease (CAD) in the United States.

According to the company, the new CCTA indication provides a noninvasive approach for health care practitioners to image and diagnose the coronary arteries of patients with suspected CAD. With Visipaque’s CCTA label extension, a CCTA can be performed with an FDA- approved contrast agent in an outpatient procedure.

GE Healthcare advised that the label extension approval for Visipaque 320 mg iodine/mL for CCTA was evaluated in two prospective, multicenter clinical studies in a total of 1,106 adult patients. Data from the two studies showed that Visipaque has a 99% negative predictive value in the diagnosis of CAD (Study 1: sensitivity, 76-89%; specificity, 84-89%. Study 2: sensitivity, 95%; specificity, 87%).

In GE Healthcare's announcement, Matt Budoff, MD, commented, “Coronary heart disease is a major cause of death in the United States. We are excited about the label extension of Visipaque as the first FDA approved iodinated contrast media for use in CCTA. Having an approved contrast agent for CCTA may facilitate the use of CCTA as a gatekeeper to ICA in patients with mild to moderate coronary artery disease, sparing patients from a more invasive procedure and long recovery times.” Dr. Budoff is Professor of Medicine at David Geffen School of Medicine at UCLA in Los Angeles, California.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.